Delivering umbilical cord mesenchymal stem cell exosomes through hydrogel ameliorates vaginal atrophy in ovariectomized rats. [PDF]
Aging (Albany NY), 2023 Background: Menopausal and postmenopausal women often experience vaginal atrophy due to estrogen deficiency. Mesenchymal stem cell exosomes have emerged as potential therapeutic agents, capable of promoting tissue regeneration and repair. Objective: This
Zhang T +5 more
europepmc +4 more sources
Number of vaginal lactobacilli in postmenopausal women with vaginal atrophy before and after treatment with erbium–YAG laser: a randomized sham-controlled trial [PDF]
BMC Women's Health, 2023 Primary objective To evaluate the effect of erbium–YAG laser on the number of vaginal lactobacilli in postmenopausal women. Secondary objectives To evaluate the effect of erbium–YAG laser on vaginal atrophy symptoms and vaginal pH in postmenopausal women.
Nuttanun Panyawongudom +2 more
doaj +3 more sources
Fecal microbiota transplantation mitigates vaginal atrophy in ovariectomized mice. [PDF]
Aging (Albany NY), 2021 Vulvovaginal atrophy (VVA) is a common menopause-related symptom affecting more than 50% of midlife and older women and cancer patients whose ovarian function are lost or damaged.
Huang J +17 more
europepmc +4 more sources
The effect of oxytocin vaginal gel on vaginal atrophy in postmenopausal women: a randomized controlled trial [PDF]
BMC Women's Health, 2020 Background Around 90% of postmenopausal women are suffering from vaginal atrophy. This study aimed to evaluate the effect of oxytocin vaginal gel on vaginal atrophy among postmenopausal women.
Ilnaz Zohrabi +5 more
doaj +3 more sources
Effect of Trigonella foenum (fenugreek) vaginal cream on vaginal atrophy in postmenopausal women
Journal of Family Medicine and Primary Care, 2020 Background and Objective: Menopause forms one-third of women's lives. During this period, many women continue their sexual activities. One of the most prevalent postmenopausal complications is vaginal atrophy whose symptoms could have destructive effects
Fakhriyeh Mazalzadeh +3 more
doaj +3 more sources
Using Wood’s Light as a Diagnostic Tool for Vaginal Atrophy [PDF]
Journal of Clinical and Diagnostic Research, 2015 Introduction: Wood’s light lamp is a device that emits ultraviolet (UV) light and is a useful diagnostic tool for dermatologic disorders. The change in the thickness of vaginal mucosa, in vaginal atrophy, causes a change in its colour under Wood’s ...
Mustafa Ulubay +5 more
doaj +3 more sources
Ospemifene for vulvar and vaginal atrophy: an overview. [PDF]
Drugs Context, 2020 The menopause-related decline in estrogen levels leads to an array of genital, sexual, and urinary symptoms collectively known as genitourinary syndrome of menopause. The constellation of symptoms associated with vulvar and vaginal atrophy (VVA) can have
Palacios S.
europepmc +4 more sources
Treatment of Vaginal Atrophy with Vaginal Estrogen Cream in Menopausal Indian Women [PDF]
Oman Medical Journal, 2017 Objectives: To measure the effect of vaginal estrogen cream in the treatment of vaginal atrophy in menopausal Indian women. Methods: A total of 50 menopausal women aged between 40 and 80 years old with symptoms of vaginal atrophy were selected and ...
Maitri Shah +5 more
doaj +3 more sources
Comparison of the Efficacy of Vaginal Hyaluronic Acid to Estrogen for the Treatment of Vaginal Atrophy in Postmenopausal Women: A Systematic Review. [PDF]
Cureus, 2023 Topical estrogen is effective for treating postmenopausal vaginal atrophy. However, there is a potential risk of estrogen-related adverse effects. There is a need for finding effective non-hormonal treatment for vaginal atrophy.
Albalawi NS +2 more
europepmc +2 more sources
Interventions Preventing Vaginitis, Vaginal Atrophy after Brachytherapy or Radiotherapy Due to Malignant Tumors of the Female Reproductive Organs-A Systematic Review. [PDF]
Int J Environ Res Public Health, 2021 Background: Radiotherapy, as a method of treatment of cervical and uterine cancers, may induce severe late-onset vaginal side effects. Unfortunately, little evidence on the management of adverse effects has been presented.
Wierzbicka A +4 more
europepmc +2 more sources